Healthcare provider profile · identity verified

Alex M Geiger, MD, MPH

Allopathic & Osteopathic Physicians|Internal Medicine · BALTIMORE, MD · NPI 1124530316

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Alex M Geiger, MD, MPH received $55.76 in general payments during 2025 across 2 reported records.

ViiV Healthcare Company accounted for 50.3% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$55.76

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
ViiV Healthcare Company Unresolved — no canonical attribution shown $28.0450.3%12025
Baxter Healthcare Unresolved — no canonical attribution shown $27.7249.7%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$28.041
Long term medical supply or device loan$27.721

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
APRETUDE
Normalized: apretude
Drug ViiV Healthcare Company $28.04 1 2025
Source payment records
Hillrom - ELI 280
Normalized: hillrom eli 280
Device Baxter Healthcare $27.72 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen20234
Atorvastatin CalciumAtorvastatin Calcium20159
Amlodipine BesylateAmlodipine Besylate11028
LisinoprilLisinopril10728
Albuterol Sulfate HfaAlbuterol Sulfate9432
Losartan PotassiumLosartan Potassium8121
GabapentinGabapentin7926
Pantoprazole SodiumPantoprazole Sodium7119
Levothyroxine SodiumLevothyroxine Sodium6720
TrulicityDulaglutide57suppressed
FurosemideFurosemide5515
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen53suppressed
OzempicSemaglutide5313
OmeprazoleOmeprazole5217
CarvedilolCarvedilol4811
Duloxetine HclDuloxetine Hcl4811
FamotidineFamotidine48suppressed
HydrochlorothiazideHydrochlorothiazide4712
Metformin HclMetformin Hcl4514
JardianceEmpagliflozin41suppressed
Trazodone HclTrazodone Hcl4112
Metoprolol SuccinateMetoprolol Succinate4012
Testosterone CypionateTestosterone Cypionate40suppressed
Venlafaxine Hcl ErVenlafaxine Hcl38suppressed
Fluoxetine HclFluoxetine Hcl3714
Lantus SolostarInsulin Glargine,hum.Rec.Anlog3712
SpironolactoneSpironolactone37suppressed
Metformin Hcl ErMetformin Hcl3613
PrednisonePrednisone3621
Escitalopram OxalateEscitalopram Oxalate3412
Cyclobenzaprine HclCyclobenzaprine Hcl3312
PregabalinPregabalin31suppressed
Rosuvastatin CalciumRosuvastatin Calcium31suppressed
DiazepamDiazepam27suppressed
Metoprolol TartrateMetoprolol Tartrate27suppressed
Tramadol HclTramadol Hcl2711
ClonazepamClonazepam26suppressed
ClopidogrelClopidogrel Bisulfate26suppressed
Sertraline HclSertraline Hcl26suppressed
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid26suppressed
EliquisApixaban25suppressed
AllopurinolAllopurinol24suppressed
Fluticasone PropionateFluticasone Propionate2313
MyrbetriqMirabegron18suppressed
Paroxetine HclParoxetine Hcl18suppressed
SimvastatinSimvastatin18suppressed
SymbicortBudesonide/Formoterol Fumarate18suppressed
TorsemideTorsemide18suppressed
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav1713
Esomeprazole MagnesiumEsomeprazole Magnesium17suppressed
Potassium ChloridePotassium Chloride17suppressed
TestosteroneTestosterone17suppressed
Triamcinolone AcetonideTriamcinolone Acetonide17suppressed
Zolpidem TartrateZolpidem Tartrate17suppressed
BaclofenBaclofen16suppressed
MeloxicamMeloxicam16suppressed
Tamsulosin HclTamsulosin Hcl16suppressed
AzithromycinAzithromycin1514
Buspirone HclBuspirone Hcl15suppressed
Dicyclomine HclDicyclomine Hcl15suppressed
FluconazoleFluconazole15suppressed
Levemir FlexpenInsulin Detemir15suppressed
MethocarbamolMethocarbamol15suppressed
NaproxenNaproxen15suppressed
Pravastatin SodiumPravastatin Sodium15suppressed
ChlorthalidoneChlorthalidone14suppressed
FarxigaDapagliflozin Propanediol14suppressed
Incruse ElliptaUmeclidinium Bromide14suppressed
Ropinirole HclRopinirole Hcl14suppressed
UrsodiolUrsodiol14suppressed
Alendronate SodiumAlendronate Sodium13suppressed
FinasterideFinasteride13suppressed
JanuviaSitagliptin Phosphate13suppressed
MinoxidilMinoxidil13suppressed
Ondansetron OdtOndansetron13suppressed
Azelastine HclAzelastine Hcl12suppressed
Droplet Pen NeedlePen Needle, Diabetic12suppressed
Estradiol ValerateEstradiol Valerate12suppressed
FenofibrateFenofibrate Nanocrystallized12suppressed
UbrelvyUbrogepant12suppressed
ClotrimazoleClotrimazole11suppressed
LevetiracetamLevetiracetam11suppressed
Methadone HclMethadone Hcl11suppressed
Spiriva RespimatTiotropium Bromide11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $55.76 · 2 records ViiV Healthcare Company APRETUDE, Hillrom - ELI 280
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error